8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported) – September 9, 2015

WEST PHARMACEUTICAL SERVICES, INC.

(Exact name of registrant as specified in its charter)

Pennsylvania	1-8036	23-1210010
(State or other jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
530 Herman O. West Drive, Exton, PA		19341-0645
(Address of principal executive offices)		(Zip Code)

 Registrant’s telephone number, including area code: 610-594-2900

Not Applicable

(Former name or address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

On September 10, 2015, West Pharmaceutical Services, Inc. ("West") management will present at CL King's 13th Annual Best Ideas Conference in New York, New York at 1:15 PM Eastern Time.

In addition, on September 16, 2015, West management will present at the 2015 Morgan Stanley Global Healthcare Conference in New York, New York at 4:15PM Eastern Time.

A copy of West's presentation materials from these conferences will be available for 30 days through the Investors link on http://www.westpharma.com, and is also attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information contained in Item 7.01 of this report (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of that section, nor will it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referencing in such filing.

Item 8.01 Other Events.

On September 9, 2015, West entered into an agreement (the "Agreement") to purchase a group annuity contract from Metropolitan Life Insurance Company ("MetLife") to settle approximately $140.0 million of its approximate $315.0 million of outstanding pension benefit obligations under the West Pharmaceutical Services, Inc. Employees' Retirement Plan (the "Plan"). MetLife was selected by the Plan's fiduciary, with the advice of an independent expert.

In connection with the Agreement, MetLife will assume the obligation to pay future pension benefits and provide administrative services beginning November 1, 2015 for approximately 1,750 West retirees and surviving beneficiaries who retired before January 1, 2015 and are currently receiving payments from the Plan.

The purchase is being funded directly by the assets of the Plan. In addition, West expects to make an additional contribution of approximately $15.0 million to the Plan in order to maintain the Plan's funded status as of the transaction date. This contribution will be funded by cash on hand and debt financing, and it will be incremental to West's previous assumption of 2015 pension plan contributions of $23.3 million.

A copy of the press release issued by West announcing the transaction is filed as Exhibit 99.2 hereto and is incorporated herein by reference.

West expects to recognize a non-cash, one-time pension settlement charge of approximately $50.0 million pre-tax (approximately $31.0 million after tax) in the third quarter of 2015.

Forward-Looking Information

This Current Report on Form 8-K ("Form 8-K") contains a number of forward-looking statements, all of which are based on West's current expectations regarding future events and speak only as of the date of this Form 8-K. These forward-looking statements involve a number of risks and uncertainties. For a description of certain factors that could cause West's future results to differ from those expressed in any such forward-looking statements, see the risk factors disclosed in Part I, Item 1A of the company's Annual Report on Form 10-K for the year ended December 31, 2014. Except as required by law or regulation, we do not intend to update any forward-looking statements.

Item 9.01 Financial Statements and Exhibits.

(d)	Exhibits
	Exhibit 99.1	West Pharmaceutical Services, Inc. Investor Presentation.
	Exhibit 99.2	West Pharmaceutical Services, Inc. Press Release, dated September 10, 2015.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	WEST PHARMACEUTICAL SERVICES, INC.
	/s/ William J. Federici
	William J. Federici
	Senior Vice President and Chief Financial Officer
September 10, 2015

3

EXHIBIT INDEX

Exhibit No.	Description
99.1	West Pharmaceutical Services, Inc. Investor Presentation.
99.2	West Pharmaceutical Services, Inc. Press Release, dated September 10, 2015.

4

EX-99.1

1 West Pharmaceutical Services, Inc. Fall Investor Relations Conferences New York, NY September, 2015

2 Safe harbor statement Cautionary Statement Under the Private Securities Litigation Reform Act of 1995 This presentation and any accompanying management commentary contain “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about product development and operational performance. Each of these estimates is based on preliminary information, and actual results could differ from these preliminary estimates. We caution investors that the risk factors listed under “Cautionary Statement” in our press releases, as well as those set forth under the caption "Risk Factors" in our most recent Annual Report on Form 10-K as filed with the Securities and Exchange Commission and as revised or supplemented by our quarterly reports on Form 10-Q, could cause our actual results to differ materially from those estimated or predicted in the forward-looking statements. You should evaluate any statement in light of these important factors. Except as required by law or regulation, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise. Non-U.S. GAAP Financial Measures Certain financial measures included in these presentation materials, or which may be referred to in management’s discussion of the Company’s results and outlook, have not been calculated in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), and therefore are referred to as non-U.S. GAAP financial measures. Non-U.S. GAAP financial measures should not be considered in isolation or as an alternative to such measures determined in accordance with U.S. GAAP. Trademarks West and the diamond logo and By your side for a healthier world™, NovaPure®, EnvisionTM, Westar®, ConfiDose®, SelfDose®, and FluroTec® are trademarks or registered trademarks of West Pharmaceutical Services, Inc., in the United States and other jurisdictions. SmartDose® is a registered trademark of Medimop Medical Projects Ltd., a subsidiary of West Pharmaceutical Services, Inc. Daikyo Crystal Zenith® is a registered trademark of Daikyo Seiko, Ltd. Daikyo Crystal Zenith® technology is licensed from Daikyo Seiko, Ltd. érisTM is a trademark of Tech Group Europe Limited. The éris safety syringe system is not available for sale in the United States and its territories.

3 Who we are By your side… Every day, injectable drugs are administered to improve the lives of millions of patients around the world. West works side-by-side with its pharmaceutical, biopharmaceutical, generic and medical device partners to design and manufacture packaging and delivery systems that will bring their drugs from concept to the patient efficiently and reliably.

4 An integral part of the healthcare industry Top 35 injectable biologics rely on West and Daikyo components ~40 Billion components manufactured annually >100 million contract manufactured components & assemblies for pens and auto-injectors annually

5 West business—at a glance 2014 Sales by Category No customer greater than 8% of sales Operations in 20 countries & 27 sites 7,000 Employees 7% 21% 35% 31% 6% 31%  High-Value Packaging  Standard Packaging  Disposable Components  Proprietary Devices  Contract Manufacturing 2014 Sales by Geography 49% 44% 7% Pharmaceutical Packaging Systems  Americas  Europe, Middle East, Africa  Asia Pacific Pharmaceutical Delivery Systems

West’s role in delivering medicines to patients Pharmaceutical Packaging Systems (PPS)  Designed-in primary packaging • Stoppers • Seals • Prefilled solutions  Lab Services  Regulatory Expertise PPS $1.0B PDS $0.4B Pharmaceutical Delivery Systems (PDS)  Proprietary products: • Self-Injection Devices • CZ Vials • Drug Reconstitution & Administration  Contract Manufacturing: • Engineering • Project Management • Tooling 6 Chart reflects 2014 relative revenues of $1.4 billion

West business growth 2010 2011 2012 2013 2014 6.1% CAGR $1,104.7 $1,421.4 2010 2011 2012 2013 2014 $0.95 $1.75 2010 2011 2012 2013 2014 + 260 BPS 7.6% 10.2% Sales 2010 – 2014 ($ millions) Diluted EPS 2010 – 2014 ROIC 2010 – 2014 7 6.1% CAGR Strong sales & EPS growth and ROIC expansion 10.5% CAGR +260 BPS

8 Circles reflect relative size of 2014 sales--PPS Sales: PDS Sales: Disposable Components Standard Packaging High-Value Products -5% 0% 5% 10% 15% 20% 25% 0% 30% 60% Category Gross Margin % Proprietary Contract Manufacturing 2014 GM 31.5% 5-Yr Sales CAGR 6.4% Product sales & margin growth 2010-2014 compound annual sales growth rates (excludes currency) High-Value Products (PPS) have driven growth Proprietary Products (PDS) present significant growth opportunity Strong Contract Manufacturing and Standard Packaging businesses 5 Year CAGR

9 Market trends support growth opportunities West believes it is well positioned to offer packaging & delivery options to address customer needs Increase in Generics & Biosimilars Biologic Product Pipelines Demand for Alternative Treatment & Delivery Options Aging Population & Developing Economies Increased Demand Increasing Quality Standards in Manufacturing

10 Our growth initiatives  Increase high-value product utilization  Operational Excellence • HVP manufacturing expansion across geographies to build capacity • Quality Culture Initiative  Increase adoption of Daikyo Crystal Zenith® systems & SmartDose® injector  Maximize contract manufacturing contribution

11 High-value product strategy Coated Washed Sterilized Camera Inspected Top Quality West can deliver increasing levels of quality to suit particular customer and drug requirements

12 Geographic expansion  Initiated Waterford, Ireland expansion • Phase 1 commenced in 7/15 • Expected to be operational by 2018  Expanded Kinston site to include high-value processing for components • Dual sourcing/risk mitigation • Commercial orders Q3  Adding high-value product capacity in Singapore

13 Ease of use, compliance, accuracy, human factors Safety, efficacy, dosage, frequency Synergy, functionality, manufacture, preparation Stability, quality, materials, filling Proprietary product strategy Patient Dru g D e li v e ry D e v ic e Primary Container Integrated Drug Delivery System

14 CZ and SmartDose uptake  SmartDose® Electronic Wearable Injector • Opportunity for a growing number of large-volume biologics • Preference for at-home use • 8 active development projects (including Phase III) • Increased manufacturing capacity in Arizona  Daikyo Crystal Zenith® Vials and Syringes • Utility increasing for a growing number of sensitive biologics and vaccines  Cold storage, silicone sensitivity, delamination • Multiple formats available (vials, syringes, bulk) • Clinical studies ongoing: 5 mL cartridges; 1 mL long insert needle

15 Contract Manufacturing supports customers  Achieving our goals for growth in drug delivery & diagnostics • Auto-Injector growth • Rapid growth in alternative injectable delivery systems and point-of-care diagnostics  Key partner in the growing diabetes market  Completion of quality control initiative in North America  Received Frost & Sullivan Manufacturing Leadership Award

16  Key partner to pharmaceutical, biotech, generic and medical device customers  “Sticky” core business – significant barriers to entry  Strong competitive position • Diversified customer base • Maturing proprietary technology pipeline • Global footprint with strong position in fast growing Asian markets • A commitment to quality  Market drivers support business model  High-value products & proprietary devices expected to drive sales growth and margin expansion  Financial strength to invest • Strong balance sheet and operating cash flow Take-away messages

17 West Pharmaceutical Services, Inc.

EX-99.2

Exhibit 99.2

Contacts: General Media Inquiries:	Investors and Financial Media:
Emily Denney Senior Director, Communications (610) 594-3035	Michael A. Anderson Vice President and Treasurer (610) 594-3345	John Woolford Westwicke Partners (443) 213-0506

West to Purchase Group Annuity Contract for Retiree Pension Benefits

Reduces pension obligation by 44%

Exton, PA September 10, 2015 - West Pharmaceutical Services, Inc. (“West”, NYSE:WST) today announced that it has entered into an agreement to purchase a group life annuity contract from Metropolitan Life Insurance Company (MetLife) to settle approximately $140 million, or 44% of its approximately $315 million of outstanding U.S. pension obligations. MetLife will assume the obligations to pay future pension benefits starting November 1, 2015, for specified U.S. retirees and surviving beneficiaries who retired before January 1, 2015 and are currently receiving payments from West’s retirement annuity program.

West remains committed to meeting its pension obligations and the purchase of the annuity contract[s] allows the company to fund the benefits of its approximately 1,750 retirees while reducing volatility in pension costs and funding requirements. MetLife was selected by the Plan’s fiduciary – with the advice of an independent expert – following a rigorous evaluation process. The selection was based on many factors, including the insurance company’s financial strength and rating, its ability to administer plan payments, and its customer service capabilities.

The annuity purchase will not impact the amount or timing of monthly pension benefits that West retirees and their beneficiaries are receiving today. MetLife has irrevocably committed to making those payments to retirees under the annuity contract. MetLife will notify those affected by the forthcoming change by mail, and will be providing a customer service number to address any questions that those retirees may have.

The purchase is being funded from current plan assets. Although not required, West anticipates making an additional contribution of approximately $15 million to its U.S. retirement plan, which is intended to restore the plan’s funded status following the annuity purchase to that which existed immediately prior to the purchase. West expects to incur a non-cash pension settlement charge of approximately $50 million in the third quarter.

About West

West Pharmaceutical Services, Inc. is a leading manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. Working by the side of its customers from concept to patient, West creates products that promote the efficiency, reliability

and safety of the world's pharmaceutical drug supply. West is headquartered in Exton, Pennsylvania, and supports its customers from locations in North and South America, Europe, Asia and Australia. West's 2014 sales of $1.42 billion reflect the daily use of approximately 110 million of its components and devices, which are designed to improve the delivery of healthcare to patients around the world.

About Metropolitan Life Insurance Company

Metropolitan Life Insurance Company (MetLife), a wholly owned subsidiary of MetLife, makes benefit payments to more than 520,000 annuitants each month and has $391.9 billion in total assets and $16.8 billion in total capital as of December 31, 2014. MetLife, Inc. ranks among the top-rated insurance holding companies in North America.